Organisation paid for research Program year 2025 Source: CMS Open Payments

Vance Thompson Vision Clinic Prof LLC

Neither a doctor nor a teaching hospital

Research payments

$1,963,287

416 payments

Through program year 2025, Vance Thompson Vision Clinic Prof LLC is reported as receiving $1,963,287 in research payments, across 416 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $105,102 20
2024 Research $332,095 335
2023 Research $211,393 7
2022 Research $781,329 22
2021 Research $398,646 19
2020 Research $123,043 9
2019 Research $11,680 4

Breakdown

Who paid Research payments · program years 2019–2025
  1. Oyster Point Pharma, Inc. $622,960 9 payments
  2. Bausch Health US, LLC $341,848 19 payments
  3. RxSight Inc $301,648 331 payments
  4. Novartis Pharmaceuticals Corporation $296,460 2 payments
  5. Sight Sciences, Inc. $246,488 37 payments
  6. Ocular Therapeutix, Inc. $141,069 15 payments
  7. Genentech, Inc. $12,815 3 payments
Studies the money was for Research payments · program years 2019–2025
  1. RxSight Light Adjustable Lens and Light Delivery Device New Enrollment Study $301,648 331 payments
  2. A Randomized, Placebo-Controlled, Double-Masked, Multi-Center, Dose-Ranging Study to Evaluate the Safety, and Efficacy of Unr844 in Subjects With Presbyopia $286,524 1 payment
  3. A Prospective, Multicenter, Randomized, Active-Controlled Clinical Study to Evaluate the Safety and Effectiveness of the Envista One-Piece Hydrophobic Acrylic Trifocal Intraocular Lens in Subjects Undergoing Cataract Extraction $274,446 8 payments
  4. A Randomized, Controlled, Double-Masked, Two-Arm Investigator-Initiated Study to Assess the Efficacy of Oc-01 (Varenicline) Nasal Spray on Signs and Symptoms of Dry Eye Disease in Subjects Following Laser-Assisted in Situ Keratomileusis (Lasik) $186,179 2 payments
  5. A Randomized, Controlled, Double-Masked, Two-Arm Investigator-Initiated Study to Assess the Efficacy of Oc-01 (Varenicline) Nasal Spray on Signs and Symptoms of Dry Eye Disease in Subjects Following Corneal Collagen Crosslinking (CXL) $158,140 2 payments
  6. Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration $101,592 14 payments
  7. A Randomized, Controlled, Double-Masked, Two-Arm Investigator-Initiated Study to Assess the Efficacy of Oc-01 (Varenicline) Nasal Spray on Signs and Symptoms of Dry Eye Disease Following Photorefractive Keratectomy (PRK) $83,318 1 payment
  8. A Randomized Controlled Double-Masked Two-Arm Investigator-Initiated Study to Assess the Efficacy of Oc-01 (Varenicline) Nasal Spray on Signs and Symptoms of Dry Eye Disease Following Photorefractive Keratectomy (PRK) $83,280 1 payment
  9. A Randomized Controlled Double-Masked Two-Arm Investigator-Initiated Study to Assess the Efficacy of Oc-01 (Varenicline) Nasal Spray on Signs and Symptoms of Dry Eye Disease in Subjects Following Laser-Assisted in Situ Keratomileusis (Lasik) $71,763 2 payments
  10. Randomized Controlled Trial to Evaluate the Safety and Effectiveness of the TearCare System in the Treatment of the Signs and Symptoms of Dry Eye Disease $68,220 4 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record